Research programme: autologous chimeric antigen receptor T cell therapies - Poseida Therapeutics

Drug Profile

Research programme: autologous chimeric antigen receptor T cell therapies - Poseida Therapeutics

Alternative Names: Autologous CAR T-cell therapies - Poseida Therapeutics; Autologous CAR-based immuno-oncology therapeutics - Poseida; Autologous CAR-T therapies - Poseida Therapeutics; P-BCMA-101

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Poseida Therapeutics
  • Developer Janssen Biotech; Poseida Therapeutics
  • Class CAR-T cell therapies
  • Mechanism of Action T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Multiple myeloma; Solid tumours

Most Recent Events

  • 05 Dec 2016 Pharmacodynamic data from a preclinical trial in multiple myeloma presented at the 58th American Society of Haematology Annual Meeting (ASH-2016)
  • 05 Dec 2016 Poseida Therapeutics plans a phase I trial for Multiple myeloma presumably in USA
  • 11 Aug 2015 Poseida Therapeutics in-licenses Centyrin technology from Janssen Biotech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top